Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia. 

Abbott Espirit BTK Bioresorbable stent, or bioresorbable vascular scaffold (BVS) measures 99 microns and is made from poly-L-lactide (PLLA), a semi-crystalline bioresorbable polymer engineered to resist vessel recoil and provide a platform for drug delivery. Abbott Absorb
Feature | Stents Bioresorbable

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
News | Atherectomy Devices

July 20, 2020 – BD (Becton, Dickinson and Company) recently completed the acquisition of Straub Medical AG, a privately ...

Home July 20, 2020
Home
News | Peripheral Artery Disease (PAD)

June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent ...

Home June 16, 2020
Home
News | Peripheral Artery Disease (PAD)

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

Home March 28, 2020
Home
Medicare, CMS, calls for cancelling or postponing all elective or non-essential medical procedures, test and surgeries due to COVID-19. #COVID19 #SARcov2 #coronavirus #cardiology
Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

March 20, 2020 — The Centers for Medicare and Medicaid Services (CMS) announced March 18, 2020, that all elective ...

Home March 20, 2020
Home
News | Atherectomy Devices

February 13, 2020 — The U.S. Food and Drug Administration (FDA) has issued its final guidance on "Peripheral Vascular ...

Home February 13, 2020
Home
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.
Feature | Stents | Saloni Walimbe

Cardiovascular diseases (CVDs) are among the leading causes of death across the globe. For patients suffering from high ...

Home February 11, 2020
Home
The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA.
Feature

December 16, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 17, 2019
Home
News

November 21, 2019 — The U.S. Food and Drug Administration (FDA) has cleared the Medtronic In.Pact AV drug-coated balloon ...

Home November 26, 2019
Home
News | Peripheral Artery Disease (PAD)

November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical ...

Home November 14, 2019
Home
News | Peripheral Artery Disease (PAD)

November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded trial ...

Home November 14, 2019
Home
News | Peripheral Artery Disease (PAD)

November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the ...

Home November 14, 2019
Home
News | Drug-Eluting Balloons

November 7, 2019 — The IN.PACT Arteriovenous (AV) Access randomized trial evaluating the safety and effectiveness of the ...

Home November 14, 2019
Home
News | Atherectomy Devices

November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and ...

Home November 11, 2019
Home
News | Stents Carotid

November 11, 2019 — Although common femoral artery (CFA) endarterectomy is still considered the gold standard treatment ...

Home November 11, 2019
Home
Subscribe Now